Iterum Therapeutics plc (ITRM) Earnings History

Iterum Therapeutics plc - Q3 2025 Earnings

Filed at: Nov 13, 2025, 7:00 PM EST|Read from source

EXECUTIVE SUMMARY

Iterum Therapeutics launched its first commercial product, ORLYNVAH™, in August 2025 for uncomplicated urinary tract infections, anticipating modest 2025 sales and projecting $5-15 million in 2026. The company has extended its cash runway into Q2 2026, but incurred increased SG&A expenses due to the launch, leading to a wider net loss compared to the prior year.

POSITIVE HIGHLIGHTS

  • •

    ORLYNVAH™ commercially launched in the United States in August 2025.

    positive
  • •

    Cash runway extended into Q2 2026.

    positive
  • •

    Granted new patents in China (expiring March 2041) and Mexico (expiring December 2039) covering combinations of sulopenem etzadroxil, probenecid, and valproic acid.

    positive
  • •

    Presented at IDWeek 2025, highlighting ORLYNVAH™ and uUTI treatment.

    neutral

CONCERNS & RISKS

  • •

    Net loss increased to $9.0 million in Q3 2025 from $6.1 million in Q3 2024.

    negative
  • •

    Non-GAAP net loss increased to $7.3 million in Q3 2025 from $4.8 million in Q3 2024.

    negative
  • •

    Selling, general and administrative expenses increased significantly to $6.5 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to the commercialization of ORLYNVAH™.

    attention
  • •

    Cash and cash equivalents decreased to $11.0 million as of September 30, 2025, from $24.1 million as of December 31, 2024.

    negative
  • •

    Total assets decreased from $44.6 million as of December 31, 2024, to $32.5 million as of September 30, 2025.

    negative
  • •

    Total liabilities decreased from $48.7 million as of December 31, 2024, to $39.9 million as of September 30, 2025, but the company still has a shareholders' deficit.

    negative

FINANCIAL METRICS

Revenue
Quarterly
$390.00K
N/A
Net Income
Quarterly
$-8.98M
N/A
Prior year: $-6.09M
Annual (YTD)
$-20.38M
N/A
Prior year: $-18.19M
EPS (Diluted)
Quarterly
$-0.20
N/A
Prior year: $-0.30
Operating Income
Quarterly
$-7.73M
N/A
Prior year: $-4.89M
Annual (YTD)
$-16.97M
N/A
Prior year: $-15.03M
EPS (Basic)
Quarterly
$-0.20
N/A
Prior year: $-0.30

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

MANAGEMENT GUIDANCE

2026

Net product sales of ORLYNVAH™
$5000.0B—$15000.0B
Mid-point: $10000.0B
"Guidance depends on uptake and payer coverage."

Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.

MANAGEMENT COMMENTARY

Thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs).

— Iterum Therapeutics plc, Q3 2025 2025 Earnings Call

The significance of this milestone cannot be overstated—particularly given the importance of bringing a new treatment option to the uUTI space where antibiotic resistance continues to erode the efficacy of existing oral therapies and there have been no new branded launches for over 25 years.

— Iterum Therapeutics plc, Q3 2025 2025 Earnings Call

Given our limited commercial infrastructure and consistent with historical antibiotic launches, we anticipate modest sales in 2025.

— Iterum Therapeutics plc, Q3 2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Ordinary shares outstanding
52.8M
shares

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.